Maurizio Facheris - Concepedia

Author

Maurizio Facheris

Also Known As

Alicia Garrido, Johan G Eriksson, M. F. Facheris, M. Facheris, M.F. Facheris, Maurizio F Facheris, Maurizio F. Facheris, Maurizio Facheris, Maurizio Francesco Facheris, P. P. Pramstaller

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

AbbVie (United States)Eurac Research University of Lübeck Ospedale di Bolzano Michael J. Fox Foundation

About

Maurizio Facheris is an author at AbbVie (United States) specializing in medicine, neurology, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	728
2	Health Sciences	1	1	71
3	Social Sciences	1	1	40
4	Anesthesia	1	1	40
5	Cell Biology	1	1	12

Maurizio Facheris

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index Elizabeth K. Speliotes, Cristen J. Willer, S. I. Berndt, Carolina Digital Repository (University of North Carolina at Chapel Hill)	2010	767
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial Michael J. Soileau, Jason Aldred, Kumar Budur, The Lancet Neurology Advanced ParkinsonParkinson DiseaseNeurologyMedicineContinuous Subcutaneous Foslevodopa-foscarbidopa	2022	172
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study Tanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, The Lancet Neurology Dopamine TransporterParkinson DiseaseNeuroscienceNeurologyDopamine	2019	135
Large-scale replication and heterogeneity in Parkinson disease genetic loci Manu Sharma, John P. A. Ioannidis, Jan Aasly, Neurology	2012	130
Motor and nonmotor heterogeneity of <i>LRRK2</i>‐related and idiopathic Parkinson's disease Connie Marras, Roy N. Alcalay, Chelsea Caspell‐Garcia, Movement Disorders	2016	125
Overexpression of blood microRNAs 103a, 30b, and 29a in <scp>l</scp> -dopa–treated patients with PD Alice Serafin, Luisa Foco, Stefano Zanigni, Neurology	2015	119
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants Manu Sharma, John P. A. Ioannidis, Jan Aasly, Journal of Medical Genetics	2012	106
The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results Cristian Pattaro, Martin Gögele, Deborah Mascalzoni, Journal of Translational Medicine	2015	102
Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease Hubert H. Fernandez, James T. Boyd, Victor S.C. Fung, Movement Disorders	2018	93
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study Jason Aldred, Eric Freire-Álvarez, Angelo Antonini, Neurology and Therapy	2023	91

Page 1